rinvoq

Generic: upadacitinib

Labeler: abbvie inc.
NDC Directory HUMAN PRESCRIPTION DRUG NDA Inactive Finished

Drug Facts

Product Profile

Brand Name rinvoq
Generic Name upadacitinib
Labeler abbvie inc.
Dosage Form SOLUTION
Routes
ORAL
Active Ingredients

upadacitinib 1 mg/mL

Manufacturer
AbbVie Inc.

Identifiers & Regulatory

Product NDC 0074-2320
Product ID 0074-2320_13f26758-52b4-4239-9981-a4b550e740e2
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category NDA
Application Number NDA218347
Listing Expiration 2026-12-31
Marketing Start 2024-04-26

Pharmacologic Class

Established (EPC)
janus kinase inhibitor [epc]
Mechanism of Action
janus kinase inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 00742320
Hyphenated Format 0074-2320

Supplemental Identifiers

RxCUI
2196894 2196900 2590051 2590054 2596957 2596960 2681015 2681019
UNII
4RA0KN46E0
NUI
N0000190858 N0000190857

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name rinvoq (source: ndc)
Generic Name upadacitinib (source: ndc)
Application Number NDA218347 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 1 mg/mL
source: ndc
Packaging
  • 1 BOTTLE in 1 CARTON (0074-2320-01) / 180 mL in 1 BOTTLE
  • 1 BOTTLE in 1 CARTON (0074-2320-70) / 180 mL in 1 BOTTLE
source: ndc

Packages (2)

Ingredients (1)

upadacitinib (1 mg/mL)

Linked Drug Pages (1)

Raw FDA Data

View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "13f26758-52b4-4239-9981-a4b550e740e2", "openfda": {"nui": ["N0000190858", "N0000190857"], "unii": ["4RA0KN46E0"], "rxcui": ["2196894", "2196900", "2590051", "2590054", "2596957", "2596960", "2681015", "2681019"], "spl_set_id": ["2966aec7-2ef0-923c-d8ff-fe1a957bf095"], "pharm_class_epc": ["Janus Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Janus Kinase Inhibitors [MoA]"], "manufacturer_name": ["AbbVie Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 BOTTLE in 1 CARTON (0074-2320-01)  / 180 mL in 1 BOTTLE", "package_ndc": "0074-2320-01", "marketing_start_date": "20240426"}, {"sample": true, "description": "1 BOTTLE in 1 CARTON (0074-2320-70)  / 180 mL in 1 BOTTLE", "package_ndc": "0074-2320-70", "marketing_start_date": "20240426"}], "brand_name": "Rinvoq", "product_id": "0074-2320_13f26758-52b4-4239-9981-a4b550e740e2", "dosage_form": "SOLUTION", "pharm_class": ["Janus Kinase Inhibitor [EPC]", "Janus Kinase Inhibitors [MoA]"], "product_ndc": "0074-2320", "generic_name": "Upadacitinib", "labeler_name": "AbbVie Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Rinvoq", "active_ingredients": [{"name": "UPADACITINIB", "strength": "1 mg/mL"}], "application_number": "NDA218347", "marketing_category": "NDA", "marketing_start_date": "20240426", "listing_expiration_date": "20261231"}